文献速递神经肿瘤

WHO 3级IDH突变胶质瘤术后选择vorasidenib的动因与临床过程:初步经验

Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.
PubMed 文献 · J Neurooncol · 2026-01-28

回顾性分析4家神经肿瘤中心10例WHO 3级IDH突变胶质瘤患者,术后仅接受vorasidenib 40 mg每日。所有病例因KPS 90-100%、无局灶神经症状且无需皮质类固醇而选择该药。6个月和12个月PFS分别为90%和77.1%,1例出现3级肝酶升高需减量。初步疗效与安全性与INDIGO试验一致。

要点

  • 保留的临床状态(KPS 90-100%、无神经症状、无需激素)是选择vorasidenib的主要动因。
  • 术后单用vorasidenib的6个月和12个月PFS分别为90%和77.1%。
  • 1例出现3级肝酶升高需减量,需监测肝功能。

核心结论

  • 保留的临床条件指导所有病例选择IDH突变抑制剂,初步疗效与安全性与INDIGO试验一致。

研究设计与样本

  • 回顾性综述4家参考神经肿瘤中心收治的WHO 3级IDH突变胶质瘤患者临床数据。
  • 患者仅接受手术治疗,并在药物早期准入计划中符合vorasidenib 40 mg每日条件。
  • 共纳入10例患者(6例星形细胞瘤,4例少突胶质细胞瘤)。

主要发现

  • 良好KPS(90-100%)、无局灶神经体征/症状且无需皮质类固醇指导所有10例选择vorasidenib。
  • 6个月PFS为90%,12个月PFS为77.1%。
  • 1例(10%)出现3级肝酶升高,需减量。

临床怎么用

  • 对于术后WHO 3级IDH突变胶质瘤患者,若KPS 90-100%、无神经症状且无需激素,可考虑vorasidenib。
  • 使用vorasidenib期间需监测肝功能,出现3级肝酶升高时应减量。

局限性

  • 回顾性设计,样本量小(10例),为初步经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: According to most of international guidelines, patients with newly diagnosed IDH mutant (IDHm) gliomas should receive maximal safe resection followed by a wait-and-see strategy, the IDH mutation inhibitor vorasidenib or sequential radio-chemotherapy (RT/CT) based on risk factors of progression such as extent of resection, neurological symptoms and WHO grading. However, it is not clear how the historical risk factors of progression should drive decision-making in molecular era. It is still unknown whether IDH inhibition may be appropriate in patients with WHO grade 3 IDHm gliomas, particularly when expected tumour growth rate is slow and delaying RT/CT is not a concern. METHODS: We retrospectively reviewed the clinical data of patients with WHO G3 IDHm gliomas in 4 reference neuro-oncological centres. The patients were treated only with surgery and were considered eligible for vorasidenib at the dose of 40 mg daily within the drug early access programme. RESULTS: A total of 10 patients were included (6 astrocytoma, 4 oligodendroglioma). Good Karnofsky performance status (90-100%), no neurological focal signs/symptoms and no need of corticosteroid guided the choice of vorasidenib in all cases (10/10). The 6 month and 12 month-PFS were 90% and 77.1%, respectively. In one case (10%) there was a grade 3 elevation in liver function tests, necessitating dose reduction. CONCLUSIONS: Preserved clinical conditions guided the choice of IDH mutation inhibitor in all cases, with preliminary efficacy and safety data consistent with those of the INDIGO trial. Future studies should address the most appropriate role of vorasidenib in this setting.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Dipasquale A, Giordano P, Bosio A, et al. Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience. J Neurooncol. 2026. PMID: 41604034. doi:10.1007/s11060-026-05439-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。